Share
Print-Friendly PDF Print this page

Mitchell Bloom is national Chair of Goodwin Procter’s Life Sciences Practice. Mr. Bloom specializes in representing public and private life science companies, as well as venture capital firms and investment banks focused on the life sciences sector, including matters involving biotechnology, medical devices, diagnostics and healthcare information technology.

Chambers USA: America’s Leading Lawyers for Business, The Legal 500 and LMG Life Sciences have all recognized Mr. Bloom as a national industry leader for his corporate finance and life sciences expertise.

Mr. Bloom's practice is focused on the representation of emerging and public life science companies and he serves as principal outside or general counsel to leading life science companies. In addition to day-to-day corporate counseling and strategic advice to his clients, he regularly handles a variety of major business transactions, including public offerings, mergers and acquisitions, venture capital financings and strategic collaborations and commercial transactions.

His recent client representations include work with:

  • Global Blood Therapeutics in its $120 million initial public offering
  • Galapagos NV in its $275 million initial public offering
  • Neos Therapeutics in its $75 million initial public offering
  • Celyad SA in its $100 million initial public offering
  • MyoKardia in its $46 million Series B financing
  • Voyager Therapeutics in its strategic collaboration with Genzyme for $100 million upfront and up to $745 million in milestone payments, and in its $45 million Series A and $60 million Series B financings
  • SAGE Therapeutics in its $90 million initial public offering and $138 million follow-on public offering
  • Esperion in its $70 million initial public offering and subsequent  $97 million and $201 million  follow-on public offerings
  • Alnylam Pharmaceuticals in its $450 million follow-on public offering and in its strategic alliance and $700 million equity financing with Genzyme
  • Jounce Therapeutics in its $47 million Series A and $56 million Series B financings
  • Zafgen in its $96 million initial public offering and subsequent $137 million follow-on public offering
  • Inotek Pharmaceuticals in its $60 million initial public offering and $68.9 million follow-on public offering
  • DBV Technologies SA in its $92 million initial public offering
  • ProQR Therapeutics B.V. in its $97.5 million initial public offering
  • Nimbus Therapeutics in connection with innovative collaborations with Monsanto and Shire Plc and in its $43 million Series B financing
  • Warp Drive Bio in its innovative strategic partnership with Sanofi
  • Mevion Medical Systems in connection with its $55 million equity and debt financing and proposed initial public offering
  • Representation of underwriters in connection with public offerings for Intrexon Corporation, Roka Biosciences, Tokai Pharmaceuticals, Flexion Therapeutics, NPS Pharmaceuticals, and Regulus Therapeutics

Mr. Bloom is recognized nationally for his leadership in the life sciences industry and has been included in numerous legal guides for his corporate finance and life sciences expertise, including Chambers USA: America’s Leading Lawyers for Business, U.S. News-Best Lawyers and The Legal 500 United States. In addition, for the past two years he has been selected as a “Life Science Star” by LMG Life Sciences.

Under his leadership, Goodwin Procter’s Life Sciences Practice has received numerous awards and honors, including U.S. News’ Biotechnology Law Firm of the Year for three years running (2013-2015) and perennial nationwide recognition by Chambers USA.

Prior to joining Goodwin Procter, Mr. Bloom was a partner at Testa, Hurwitz & Thibeault in Boston, where he was a member of the Business Practice Group and co-chair of its Life Sciences Practice.

Mr. Bloom is a member of the American, Massachusetts and Boston Bar Associations.

A New Paradigm for Venture Funds
The Metropolitan Corporate Counsel
September 1, 2007